Every 10-Q that Replimune Group, Inc. (REPL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow REPL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full REPL filings page.
Replimune Group, Inc. reported a quarterly net loss of $69.8 million for the three months ended June 30 2026, improving from $86.7 million a year earlier as total operating expenses declined to $68.2 million from $90.4 million, driven by lower research and development and selling, general and administrative costs.
Cash, cash equivalents and short‑term investments totaled $195.3 million at June 30 2026, supplemented by approximately $141.0 million in net proceeds from an August 2026 equity offering. The company states this liquidity, together with its plan, is expected to fund operations for more than 12 months, including commercialization of TUDRIQEV.
Subsequent to quarter end, the FDA granted accelerated approval for TUDRIQEV (vusolimogene oderparepvec‑wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma progressing on anti‑PD‑1 therapy, and commercial launch is in progress. Long‑term debt under the Hercules facility stood at $84.1 million, with interest‑only payments and maturity now extended to October 1 2029.
Replimune Group reported a larger net loss as it continues investing heavily in its oncolytic immunotherapy pipeline. For the nine months ended December 31, 2025, the company recorded a net loss of $240.7 million, compared with $173.2 million a year earlier, driven mainly by higher research and development and selling, general and administrative expenses.
Cash and cash equivalents were $122.9 million and short‑term investments were $146.2 million as of December 31, 2025, and management believes this liquidity can fund operations for at least 12 months, including potential RP1 commercialization. The balance sheet also shows $47.6 million of long‑term debt with Hercules Capital and total lease liabilities of $28.7 million.
Clinically, the FDA issued a complete response letter for the RP1 BLA in advanced melanoma in July 2025, but later accepted a resubmitted BLA with a new PDUFA date of April 10, 2026. Replimune is running the Phase 3 IGNYTE‑3 confirmatory trial in anti‑PD‑1 failed melanoma and the REVEAL Phase 2/3 trial of RP2 in metastatic uveal melanoma.
The company also faces a putative securities class action, related shareholder derivative suits, a shareholder demand letter, and an SEC investigation focused on the RP1 BLA; Replimune denies wrongdoing and is cooperating with regulators.
Replimune Group (REPL) filed its quarterly report, highlighting increased R&D investment and a larger net loss as it advances lead therapy RP1. For the quarter ended September 30, 2025, operating expenses were $84.3 million (R&D $57.9 million; SG&A $26.4 million), resulting in a net loss of $83.1 million, or $0.90 per share. Cash and cash equivalents were $102.3 million and short‑term investments were $221.3 million.
Total assets were $389.5 million and stockholders’ equity was $263.3 million. Net cash used in operating activities for the six months was $158.2 million, offset by $149.2 million provided by investing activities, ending with $104.0 million in cash, cash equivalents and restricted cash. Long‑term debt, net, was $47.2 million under the Hercules facility. The company stated its cash, cash equivalents and short‑term investments are expected to fund operations for at least 12 months from issuance of the statements. The FDA accepted the resubmission of the BLA for RP1 in combination with nivolumab in advanced melanoma, with a PDUFA date of April 10, 2026.